Zhejiang Cheng Yi Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Since its establishment in 1966, Zhejiang Chengyi Pharmaceutical Co., Ltd. has actively relied on the advantages of Dongtou as a demonstration zone for marine economic development, vigorously developing marine biopharmaceuticals, and developing a small workshop style military family pharmacy into the first listed pharmaceutical enterprise in Wenzhou City and the first listed marine biopharmaceutical company in Zhejiang Province. Standardized comprehensive preparation "intelligent factory" and a garden style health industrial park covering an area of 300 acres. Since its listing in 2017, the company has maintained an annual growth rate of 20-30% and invested over 4% in research and development. In 2020, the industrial revenue exceeded 700 million yuan for the first time. At present, the company can produce over 70 varieties and nearly a hundred specifications of drugs, among which the marine biopharmaceutical "glucosamine hydrochloride" series for the treatment and prevention of systemic osteoarthritis, and the nervous system drug "gastrodin" have the first market share in similar products in China; The high-efficiency diuretic "Tolasemide" series has been included in the national torch program project; The antiviral drug "ribavirin" won the national invention patent award and was included in the national diagnosis and treatment scheme of COVID-19; Antitumor drug substance "azathioprine", drug substance "mercaptopurine" for treating childhood leukemia, and traditional Chinese patent medicines and simple preparations "Danyining Tablet" for treating cholecystitis and biliary tract infection are the company's characteristic varieties. All products have passed the national GMP certification. In 1998, international certification was first carried out, and multiple products have passed the certification of multiple countries and regions such as the US FDA, EU EMEA, Australia TGA, UK MHRA, and Mexico COFEPRIS. During the 14th Five Year Plan period, Chengyi Pharmaceutical will focus on planning the "Two Strong and One Large" projects in Asia's largest annual production of 2000 tons of ammonia sugar raw materials and 1000 tons of super fish oil industry, focusing on the big health industry, achieving the layout of the entire process, category, and industry chain from food to health products to drugs, striving to seize strategic heights, empowering enterprises with new value, achieving company collectivization and high-quality development, and striving to build the "aircraft carrier" of Zhejiang Southern Pharmaceutical, To promote the industrial fusion, urban butterfly transformation, and happy leap of Dongtou, innovate and build a common prosperity maritime garden, and accelerate the construction of Zhejiang's marine economic development demonstration zone, we will contribute our sincere efforts. |
| Headquarter | Wenzhou City |
| Establish Date | 6/22/2001 |
| Listed Code | 603811.SH |
| Listed Date | 3/15/2017 |
| Chairman | Yan Yiyi. |
| CEO | Zhao Chunjian. |
| Website | www.chengyipharma.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
